(AIM: SAR)

24 November 2009

 

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Holdings in Company

 

The Company has been notified today that, following a sale of shares, Mr and Mrs Leonard Licht hold 56,700,000 ordinary shares in the capital of the Company, equivalent to 4.82 per cent. of the issued share capital of the Company.  

Enquires: 

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

 

 

Merchant John East Securities Limited (Nominated Adviser)

Simon Clements/Bidhi Bhoma

020 7628 2200

 

 

Hybridan LLP (Broker)

 

Claire Noyce/Stephen Austin

020 3159 5085

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer.

Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR.  For further information, please visit www.sareum.co.uk